The genetic diagnostics and biotech company was founded in 1984 as a spin-off from Düsseldorf University when Riesner was a professor at the university. Originally, the company was to be called Diagen, an abbreviation for diagnostics and genetics.
However, as another company was already called DIAGEN, they decided to use the name QIAGEN. For legal reasons, the company’s headquarters are in Venlo, the Netherlands, with relatively few employees. The largest operational facility is located in Hilden with 1,300 employees. Riesner has been on the company’s supervisory board for a long time but left the position a few years ago.
Born2Invest keeps you up to date on the latest finance headlines from industries like science, banking, cannabis, and much more. Our software distills news into 500 characters or less so that no matter where you are or how busy your schedule is, you are always updated.
The shares of the genetic diagnostics and biotech company Qiagen have worked their way back up significantly in recent weeks. Between July 23 and October 8, the shares price fell by around 35%.
Now, however, a clear recovery has taken place, the shares improved by more than 60% and are trading at a new multi-year high of $41.85 (€38). In mid-November, the company had reported on a number of non-binding takeover bidders and declared that it was ready to talk.
The explosive rise in the shares’ price has visibly brightened the chart. The price is now above the 50-day line again (EMA50). This results in a buy-signal.
Looking at the year (to date), the stock is now up almost 28%. In a historical comparison, this already means a strong overperformance, as the average annual return (taking into account all yield pairs since 1998) amounts to 6.74%.
From a statistical point of view, the shares’ price could, therefore, fall sharply again and the return at the end of the year could be more than 21% points lower.
What do the analysts say about the company?
According to the analysts, the fair value of the shares averages $35.52 (€32.25) and is thus around 15% below the current price level. The Qiagen shares are currently being monitored by 11 analysts and there are 4 buy, 6 hold and one sell ratings. This leads to a neutral signal despite the lower average price target.
The bottom line is that the Qiagen stock receives 1.5 out of 3 points and is therefore neutral overall. Investors can let their profits run, but it is advisable to wait for a bullish assessment on the part of the analysts before buying or re-entering.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in FINANZTRENDS, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Historic boom for Lysogene biotech to the U.S. market
The shares of Lysogene, a biopharmaceutical company, has risen by more than 50% thanks to the granted "Fast Track" designation...
Crowdfunding in Mexico: the financial alternative of 2020
Crowdfunding in Mexico has been handled in a less obvious way for hundreds of years. Crowdfunding refers to any capital...
Aena appeals against the CNMC’s imposition of further fare reductions on airlines
The CNMC has approved the Resolution on the supervision of airport tariffs applicable by Aena in the year 2020, in...
Victim lost $5000 in a false Nubank employee scam
A 46-year-old assistant approached the Judiciary Police Central of Americana on February 18, reporting that he lost more than $5.000...
Kafo Jiginew and the EIB loan agreement estimates at $10.8 billion
The signing of a loan agreement for $10.8 billion between "Kafo Jiginew" and the European Investment Bank. It was chaired...